The introduction of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable interest within the healthcare community. This novel dual GIP and GLP-1 receptor medication suggests to offer impressive improvements in fat loss compared to previous therapies. Early patient data have indicated substantial reductions in weight , conceivably repr